U.S. pharmaceutical companies are expected to collect more revenue from COVID-19 vaccines in the third quarter than they did in the entire first half of the year, and that money should continue to grow.
Pfizer collected revenue of $11.3 billion in the first half of the year from its COVID-19 vaccine, now known as Comirnaty, and analysts project third-quarter sales of $11.86 billion. Those numbers could be a bit high, however, as some sales could get pushed into the fourth quarter, when booster shots and the newly authorized vaccine for younger children begin landing in arms.
Mizuho analysts wrote earlier this month that Pfizer might struggle to put up more than $10 billion in third-quarter COVID-19 vaccine sales, though the missing revenue would likely just be pushed into the fourth quarter instead. Moderna on average is expected to report vaccine sales of $6.17 billion in the third quarter, after collecting $5.93 billion in the first half. The vaccine is more important financially to Moderna, because it is the first approved product for the younger pharmaceutical company, but the company faces a potential delay in its own product aimed at children after a setback over the weekend.
thanks
“It’s free!” They said